oblimersen + fludarabine + rituximab

rejuvenates **Oblimersen + fludarabine + rituximab** is a three-drug combination regimen investigated for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) and other lymphoid malignancies. Oblimersen is an antisense oligonucleotide targeting Bcl-2 mRNA, thereby reducing Bcl-2 protein expression and promoting apoptosis in malignant cells. Fludarabine is a purine analog acting as a cytotoxic small molecule by inhibiting DNA polymerase and ribonucleotide reductase, leading to termination of DNA synthesis. Rituximab is a monoclonal antibody against CD20, a B-cell surface antigen, which induces cell death via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and direct apoptosis. Preclinical and clinical studies suggest that oblimersen may enhance the apoptotic effects of fludarabine and rituximab, resulting in increased response rates and molecular remissions in patients with CLL[1][5][7].

Other names

oblimersen sodium